Daiwa Securities Group’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$30.2M Sell
67,539
-3,056
-4% -$1.42M 0.09% 129
2025
Q4
$32M Buy
70,595
+3,368
+5% +$1.45M 0.1% 132
2025
Q3
$26.3M Sell
67,227
-8,605
-11% -$3.6M 0.09% 142
2025
Q2
$33.8M Buy
75,832
+4,600
+6% +$2.12M 0.12% 109
2025
Q1
$34.5M Buy
71,232
+5,504
+8% +$2.56M 0.15% 100
2024
Q4
$26.5M Buy
65,728
+7,861
+14% +$3.64M 0.12% 108
2024
Q3
$26.9M Buy
57,867
+14,194
+33% +$6.82M 0.12% 104
2024
Q2
$20.5M Sell
43,673
-255
-0.6% -$111K 0.11% 118
2024
Q1
$18.4M Buy
43,928
+6,941
+19% +$2.93M 0.1% 119
2023
Q4
$15M Buy
36,987
+351
+1% +$130K 0.09% 123
2023
Q3
$12.7M Buy
36,636
+5,572
+18% +$1.95M 0.09% 135
2023
Q2
$10.9M Buy
31,064
+106
+0.3% +$35.7K 0.07% 151
2023
Q1
$9.75M Buy
30,958
+1,296
+4% +$389K 0.07% 160
2022
Q4
$8.57M Buy
29,662
+388
+1% +$118K 0.07% 180
2022
Q3
$8.48M Buy
29,274
+1,145
+4% +$329K 0.07% 161
2022
Q2
$7.93M Buy
28,129
+1,582
+6% +$423K 0.06% 176
2022
Q1
$6.93M Buy
26,547
+3,372
+15% +$800K 0.04% 220
2021
Q4
$5.09M Buy
23,175
+1,483
+7% +$288K 0.03% 286
2021
Q3
$3.94M Buy
21,692
+1,899
+10% +$371K 0.03% 314
2021
Q2
$3.99M Buy
19,793
+932
+5% +$195K 0.03% 294
2021
Q1
$4.05M Buy
18,861
+1,698
+10% +$373K 0.03% 257
2020
Q4
$4.06M Sell
17,163
-28,290
-62% -$6.49M 0.03% 241
2020
Q3
$12.4M Buy
45,453
+14,382
+46% +$3.97M 0.11% 88
2020
Q2
$7.39M Hold
31,071
0.16% 81
2020
Q1
$7.39M Buy
31,071
+18,639
+150% +$4.28M 0.08% 131
2019
Q4
$2.72M Buy
12,432
+4
+0% +$810 0.02% 289
2019
Q3
$2.11M Buy
12,428
+622
+5% +$110K 0.02% 337
2019
Q2
$2.17M Buy
11,806
+61
+0.5% +$10.7K 0.02% 318
2019
Q1
$2.16M Buy
11,745
+858
+8% +$158K 0.02% 321
2018
Q4
$1.8M Buy
10,887
+540
+5% +$93.6K 0.02% 335
2018
Q3
$1.99M Buy
10,347
+533
+5% +$94.9K 0.02% 372
2018
Q2
$1.67M Sell
9,814
-301
-3% -$46.7K 0.01% 404
2018
Q1
$1.65M Buy
10,115
+2,553
+34% +$417K 0.01% 406
2017
Q4
$1.13M Buy
7,562
+1
+0% +$148 0.01% 476
2017
Q3
$1.15M Buy
7,561
+391
+5% +$58.9K 0.01% 435
2017
Q2
$924K Buy
7,170
+220
+3% +$26.5K 0.01% 465
2017
Q1
$760K Buy
6,950
+650
+10% +$57.2K ﹤0.01% 502
2016
Q4
$464K Buy
6,300
+250
+4% +$20.3K ﹤0.01% 563
2016
Q3
$528K Buy
6,050
+250
+4% +$23.6K ﹤0.01% 498
2016
Q2
$499K Hold
5,800
﹤0.01% 495
2016
Q1
$461K Sell
5,800
-32,400
-85% -$2.93M ﹤0.01% 499
2015
Q4
$4.81M Buy
38,200
+32,600
+582% +$3.94M 0.03% 170
2015
Q3
$583K Hold
5,600
﹤0.01% 455
2015
Q2
$691K Hold
5,600
﹤0.01% 457
2015
Q1
$661K Sell
5,600
-20,470
-79% -$2.45M ﹤0.01% 408
2014
Q4
$3.1M Buy
26,070
+17,430
+202% +$1.96M 0.02% 217
2014
Q3
$970K Buy
8,640
+2,140
+33% +$204K 0.01% 295
2014
Q2
$615K Hold
6,500
﹤0.01% 364
2014
Q1
$460K Hold
6,500
﹤0.01% 410
2013
Q4
$483K Hold
6,500
﹤0.01% 387
2013
Q3
$493K Hold
6,500
﹤0.01% 385
2013
Q2
$520K Buy
+6,500
New +$479K ﹤0.01% 402

Other funds holding VRTX

Daiwa Securities Group's VRTX Position: Q1 2026 in Review

Daiwa Securities Group reduced its Vertex Pharmaceuticals (VRTX) stake by 4.3% in Q1 2026, selling an estimated $1.42M and leaving 67,539 shares worth $30.2M. The position accounts for 0.09% of the portfolio, ranked #129.

Daiwa Securities Group first reported a position in VRTX in Q2 2013 and has held it in 52 quarters since. The position peaked at $34.5M in Q1 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Daiwa Securities Group held 67,539 shares of Vertex Pharmaceuticals worth $30.2M as of Q1 2026.
  • Daiwa Securities Group sold 3,056 Vertex Pharmaceuticals shares in Q1 2026, an estimated $1.42M.
  • Vertex Pharmaceuticals made up 0.09% of Daiwa Securities Group's portfolio in Q1 2026, its #129 holding.
  • Daiwa Securities Group first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
  • Daiwa Securities Group's Vertex Pharmaceuticals position peaked at $34.5M in Q1 2025.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Daiwa Securities Group's 13F filing for Q1 2026, filed 13 May 2026.